To evaluate the role of superselective ophthalmic artery melfalan (SSOAM) for management of advanced retinoblastoma whether as a primary or secondary treatment modality.


Ten cases of advanced stage D disease were managed by SSOAM. Seven cases presented after failure of other therapeutic modalities to control the tumor and 3 cases presented with advanced uniocular disease. SSOAM was given as initial therapy for 1-3 cycles followed by focal therapy.

Effectiveness / Safety:

Tumor control was achieved in 6 cases on follow up from 8-24 months. Tumor reactivation tended to present late. No systemic side-effects were noted from the technique.

Take home message:

Experience with SSOAM shows an important adjuvant role in control of advanced retinoblastoma. Tumor control was achieved in 60 % of cases. However, this therapeutic modality has to be watched out carefully for potential complications.